Fisiopatología y opciones de tratamiento a futuro en la encefalopatía hepática

Ferenci, 2002, Hepatic encephalopathy – definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998, Hepatology., 35, 716, 10.1053/jhep.2002.31250 Häussinger, 2000, Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?, J Hepatol., 32, 1035, 10.1016/S0168-8278(00)80110-5 Blei, 2001, Pathophysiology of brain edema in fulminant hepatic failure, revisited, Metab Brain Dis., 16, 85, 10.1023/A:1011670713730 Yurdaydin, 2001, The central opioid system in liver disease and its complications, Metab Brain Dis., 16, 79, 10.1023/A:1011618729660 Ahboucha, 2004, Pathophysiology of hepatic encephalopathy: a new look at GABA from the molecular standpoint, Metab Brain Dis., 19, 331, 10.1023/B:MEBR.0000043979.58915.41 Ozsoylu, 1985, Naloxone in hepatic encephalopathy, Am J Dis Child., 139, 749 Córdoba, 1998, Chronic hyponatremia exacerbates ammonia induced brain edema in rats after portacaval anastomosis, J Hepatol., 29, 589, 10.1016/S0168-8278(98)80154-2 Mullen, 1995, Hepatic encephalopathy after portosystemic shunts: any clues from TIPS?, Am J Gastroenterol., 90, 531 Butterworth, 2003, Pathogenesis of hepatic encephalopathy: new insights from neuroimaging and molecular studies, J Hepatol., 39, 278, 10.1016/S0168-8278(03)00267-8 Dhiman, 2010, Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver, J Gastroenterol Hepatol., 25, 1029, 10.1111/j.1440-1746.2010.06318.x Bai, 2013, L-ornithine-L-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials, J Gastroenterol Hepatol., 28, 783, 10.1111/jgh.12142 Butterworth, 2018, Efficacy of l-ornithine l-aspartate for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: systematic review and meta-analysis of randomized controlled trials, J Clin Exp Hepatol., 8, 301, 10.1016/j.jceh.2018.05.004 Poo, 1995, Serum zinc concentrations in two cohorts of 153 healthy subjects and 100 cirrhotic patients from Mexico City, Dig Dis., 13, 136, 10.1159/000171495 Sengupta, 2015, Screening for zinc deficiency in patients with cirrhosis: when should we start?, Dig Dis Sci., 60, 3130, 10.1007/s10620-015-3613-0 Bresci, 1993, Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment, Eur J Med., 2, 414 Tuerk, 2009, Zinc deficiency, Curr Opin Gastroenterol., 25, 136, 10.1097/MOG.0b013e328321b395 Takuma, 2010, Clinical trial: oral zinc in hepatic encephalopathy, Aliment Pharmacol Ther., 32, 1080, 10.1111/j.1365-2036.2010.04448.x Bajaj, 2014, Altered profile of human gut microbiome is associated with cirrhosis and its complications, J Hepatol., 60, 940, 10.1016/j.jhep.2013.12.019 Bajaj, 2014, The cirrhosis dysbiosis ratio defines changes in the gut microbiome associated with cirrhosis and its complications, J Hepatol., 60, 940, 10.1016/j.jhep.2013.12.019 Chen, 2011, Characterization of fecal microbial communities in patients with liver cirrhosis, Hepatology., 54, 562, 10.1002/hep.24423 Bass, 2004, Rifaximin treatment is beneficial for mild hepatic encephalopathy, Hepatology., 40, 64 Pedretti, 1991, Rifaximin vs neomycin on hyperammonemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial, Ital J Gastroenterol., 23, 175 Mas, 2003, Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial, J Hepatol., 38, 51, 10.1016/S0168-8278(02)00350-1 Williams, 2000, Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study, Eur J Gastroenterol Hepatol., 12, 203, 10.1097/00042737-200012020-00012 Bucci, 1993, Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy, Curr Med Res Opin., 13, 109, 10.1185/03007999309111539 Bass, 2010, Rifaximin treatment in hepatic encephalopathy, N Engl J Med., 362, 1071, 10.1056/NEJMoa0907893 Massa, 1993, Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose, Eur J Clin Res., 4, 7 Vrieze, 2014, Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity, J Hepatol., 60, 824, 10.1016/j.jhep.2013.11.034 Tarao, 1990, Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy, Gut., 31, 702, 10.1136/gut.31.6.702 Uribe, 1987, Acidifying enemas (lactitol and lactose) vs. Nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial, Hepatology., 7, 639, 10.1002/hep.1840070404 Watanabe, 1997, Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy, Hepatology., 26, 1410, 10.1002/hep.510260606 Horsmans, 1997, Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy, Aliment Pharmacol Ther., 11, 165, 10.1046/j.1365-2036.1997.118289000.x Dhiman, 2000, Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy, Dig Dis Sci., 45, 1549, 10.1023/A:1005556826152 Morgan, 1987, Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial, Hepatology., 7, 1278, 10.1002/hep.1840070617 Morgan, 1989, Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomized, cross-over study, J Hepatol., 8, 208, 10.1016/0168-8278(89)90009-3 Lunia, 2014, Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial, Clin Gastroenterol Hepatol., 12, 1003, 10.1016/j.cgh.2013.11.006 Agrawal, 2012, Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy, Am J Gastroenterol., 107, 1043, 10.1038/ajg.2012.113 Amodio, 2013, The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus, Hepatology., 58, 325, 10.1002/hep.26370 Cordoba, 2004, Normal protein diet for episodic hepatic encephalopathy: results of a randomized study, J Hepatol., 41, 38, 10.1016/j.jhep.2004.03.023 Merli, 2013, Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study, Metab Brain Dis., 28, 281, 10.1007/s11011-012-9365-z Hanai, 2017, Sarcopenia predicts minimal hepatic encephalopathy in patients with liver cirrhosis, Hepatol Res., 47, 1359, 10.1111/hepr.12873 Plank, 2008, Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial, Hepatology., 48, 557, 10.1002/hep.22367 Hiraoka, 2017, Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis, Eur J Gastroenterol Hepatol., 29, 1416, 10.1097/MEG.0000000000000986 Gluud, 2017, Branched-chain amino acids for people with hepatic encephalopathy, Cochrane Database Syst Rev., 8 Qiu, 2013, Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-KB-mediated mechanism, Proc Natl Acad Sci U S A., 110, 18162, 10.1073/pnas.1317049110 MacKenzie, 2013, Inhibition of myostatin signaling through Notch activation following acute resistance exercise, PLoS One., 8, e68743, 10.1371/journal.pone.0068743 Duarte-Rojo, 2012, Changes in peripheral blood mononuclear cells glutamine synthetase mRNA after exercise in healthy volunteers: exploring an alternative proposal for non hepatic ammonia metabolism, Rev Invest Clin., 64, 164 Adeva, 2012, Ammonium metabolism in humans, Metabolism., 61, 1495, 10.1016/j.metabol.2012.07.007 Lee, 2010, Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control, Mol Genet Metab., 100, 221, 10.1016/j.ymgme.2010.03.014 Ghabri, 2013, Glycerol phenylbutyrate in patients with cirrhosis and episodic hepatic encephalopathy: a pilot study of safety and effect on venous ammonia concentration, Clin Pharmacol Drug Dev., 2, 278, 10.1002/cpdd.18 Rockey, 2014, Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy, Hepatology., 59, 1073, 10.1002/hep.26611 Ratnakumari, 1993, Effect of L-carnitine on cerebral and hepatic energy metabolites in congenitally hyperammonemic sparse-fur mice and its role during benzoate therapy, Metabolism., 42, 1039, 10.1016/0026-0495(93)90020-O Rodrigo, 2009, Role of NMDA receptors in acute liver failure and ammonia toxicity: therapeutical implications, Neurochem Int., 55, 113, 10.1016/j.neuint.2009.01.007 Rose, 2005, Limited capacity for ammonia removal by brain in chronic liver failure: potential role of nitric oxide, Metab Brain Dis., 20, 275, 10.1007/s11011-005-7906-4 Malaguarnera, 2008, Acetyl-L-carnitine treatment in minimal hepatic encephalopathy, Dig Dis Sci., 53, 3018, 10.1007/s10620-008-0238-6 Malaguarnera, 2011, Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy, Scand J Gastroenterol., 46, 750, 10.3109/00365521.2011.565067 Malaguarnera, 2011, Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study, Am J Clin Nutr., 93, 799, 10.3945/ajcn.110.007393 Malaguarnera, 2011, Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial, Metab Brain Dis., 26, 281, 10.1007/s11011-011-9260-z Jiang, 2009, Direct evidence for central proinflammatory mechanisms in rats with experimental acute liver failure: protective effect of hypothermia, J Cereb Blood Flow Metab., 29, 944, 10.1038/jcbfm.2009.18 Butterworth, 2013, Parkinsonism in cirrhosis: pathogenesis and current therapeutic options, Metab Brain Dis., 28, 261, 10.1007/s11011-012-9341-7 Zemtsova, 2011, Microglia activation in hepatic encephalopathy in rats and humans, Hepatology., 54, 204, 10.1002/hep.24326 Zhang, 2017, Neuron-derived CCL2 contributes to microglia activation and neurological decline in hepatic encephalopathy, Biol Res., 50, 26, 10.1186/s40659-017-0130-y Murin, 2009, Expression of pyruvate carboxylase in cultured oligodendroglial, microglial and ependymal cells, Neurochem Res., 34, 480, 10.1007/s11064-008-9806-6 Chastre, 2010, Ammonia and proinflammatory cytokines modify expression of genes coding for astrocytic proteins implicated in brain edema in acute liver failure, Metab Brain Dis., 25, 17, 10.1007/s11011-010-9185-y Oria, 2014, Brain lactate in hepatic encephalopathy: friend or foe?, J Hepatol., 60, 476, 10.1016/j.jhep.2013.11.029 Butterworth, 1995, Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy, Metab Brain Dis., 10, 259, 10.1007/BF02109357 Spahr, 1996, Increased blood manganese in cirrhotic patients: relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms, Hepatology., 24, 1116, 10.1002/hep.510240523 Burkhard, 2003, Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration, Arch Neurol., 60, 521, 10.1001/archneur.60.4.521 Mishchenko, 1993, Changes in the hemato-encephalic barrier in experimental liver cirrhosis, Biull Eksp Biol Med., 116, 638, 10.1007/BF00785497 Macías-Rodríguez, 2015, Cerebral haemodynamics in cirrhotic patients with hepatic encephalopathy, Liver Int., 35, 344, 10.1111/liv.12557 Guevara, 2009, Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis, Am J Gastroenterol., 104, 1382, 10.1038/ajg.2009.293 Aschner, 2007, Manganese: recent advances in understanding its transport and neurotoxicity, Toxicol Appl Pharmacol., 221, 131, 10.1016/j.taap.2007.03.001 Stewart, 2011, The emerging physiological roles of the SLC14A family of urea transporters, Br J Pharmacol., 164, 1780, 10.1111/j.1476-5381.2011.01377.x Zwingmann, 2005, Ammonia toxicity under hyponatremic conditions in astrocytes: de novo synthesis of amino acids for the osmoregulatory response, Neurochem Int., 47, 39, 10.1016/j.neuint.2005.04.005 Dasarathy, 2011, Sarcopenia associated with portosystemic shunting is reversed by follistatin, J Hepatol., 54, 915, 10.1016/j.jhep.2010.08.032 Torres-Vega, 2015, Delivery of glutamine synthetase gene by baculovirus vectors: a proof of concept for the treatment of acute hyperammonemia, Gene Ther., 22, 58, 10.1038/gt.2014.89 Bajaj, 2017, Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial, Hepatology., 66, 1727, 10.1002/hep.29306